PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
56.85%
Positive net income growth while Biotechnology median is negative at -0.38%. Peter Lynch would view it as a strong advantage vs. struggling peers.
-0.49%
D&A shrinks yoy while Biotechnology median is -0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
No Data
No Data available this quarter, please select a different quarter.
-97.78%
SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
251.75%
Working capital of 251.75% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
214.04%
AP growth of 214.04% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
-132.83%
Other WC usage shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
No Data
No Data available this quarter, please select a different quarter.
28.81%
Operating cash flow growth exceeding 1.5x Biotechnology median of 7.47%. Joel Greenblatt would see a strong operational advantage vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.00%
Debt repayment yoy declines while Biotechnology median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.